Drug Data Classification Mechanism of Action Indication Contraindications Adverse Reaction Nursing Responsibilities

Generic Name: Pharmacologi > Reduces gastric > Active > Hypersensitivity to the drug CNS: headache, Before
Ranitidine c Class: acid secretion and duodenal ulcer and its components agitation, anxiety, > Assess patient’s GI condition before therapy.
Hydrochloride H2 receptor increases gastric and gastric ulcer > Alcohol intolerance (with vertigo, malaise > Assess patient for hypersensitivity to drug and
antagonist mucus and > To maintain some oral products) CV: arrhythmias history of acute porphyria.
Trade Name: bicarbonate healing of >History of acute porphyria GI: nausea, > Assess patient and family’s knowledge of drug
Zantac, Zantac-C, Therapeutic production, creating a duodenal ulcer > Pregnant and lactating vomiting, diarrhea, therapy.
Zantac 75 Class: protective coating on >Benign gastric women constipation, > Assess the general condition of the patient.
Anti- gastric mucosa. ulcer > children abdominal > Explain therapy to patient and to patient’s
Minimum Dose: ulcerative Competitively inhibits > > Use cautiously in patients discomfort/pain. family.
100-150 mg PO action of H2 at Gastroesophage with hepatic dysfunction GU: impotence, > Assess laboratory studies.
twice daily receptor sites at al reflux disease Adjust dosage in patients with decreased sperm > Tell patient about adverse reactions and instruct
Pregnancy parietal cells, > Erosive impaired kidney function.: count to report symptoms that occur.
Maximum Dose: Risk Category decreasing acid esophagitis Precaution: Endo: >Review all other significant and life threatening
300 mg once PO B secretion. > Pathologic > Renal or hepatic gynecomastia adverse reactions
HS hypersecretory impairment, heart rhythm EENT: blurred During
Onset: conditions, disturbances, phenylketonuria vision > Administer oral preparations before or with
Contents: PO = unknown including (effervescent tablets) Hematologic: meals at HS, to ensure adequate protection.
Magnesium IV = unknown Zollinger-Ellison > Elderly patients reversible > Inject IM undiluted deep into large muscle
Sulfate IM = unknown syndrome > Pregnant or breastfeeding granulocytopenia, > IV form may be added to TPN solutions.
> Patients with patients leukopenia, > Give antacid therapy 1 hour before or 2 hours
Availability: Peak: intractable ulcer Drug-drug Interaction: pancytopenia, after giving H2-antagonist dose
PO = 1 – 3 hours and those who > Antacid: decreased thrombocytopenia > Monitor renal and hepatic function tests, to
Capsules: 150 mg, IV = 15 mins cannot receive ranitidine absorption. Stagger Hepatic: hepatitis, detect early damage.
300 mg IM = 15 mins oral drugs doses. jaundice > Monitor for cardiac dysrythmias when giving IV
Granules: 150 mg > Propantheline: delayed Other: blurring and therapy.
infusion: 6.5 Duration: Patient’s Actual ranitidine absorption and itching at injection > Monitor CBC with differential throughout
mg/ml PO = 8 – 12 hours Indication: increased blood level site, anaphylaxis therapy.
injection: 25 IV = 8 – 12 hours > > Diazepam: May decrease and angioedema. After
mg/ml IM = 8 – 12 hours diazepam absorption. Monitor > Instruct patient to take medication as directed
syrup: 15 mg/ml patient for decreased for the full course of therapy, even if patient feels
tablets(dispensibl Absorption: About effectiveness. better. If a dose is missed, it should be taken as
e): 75 mg, 150 50% to 60% of PO > Glipizide: May increase soon as remembered but not if almost time for the
mg,300 mg dose; rapid from hypoglycemic effect next dose. Do not double doses.
tablets(effervesce parenteral sites after > Procalnamide: May decrease > Inform patient that smoking interferes with the
nt) : 25 mg, 150 IM dose renal clearance of action of histamine antagonists. Encourage patient
mg Distribution: procalnamide. to quit smoking or ate least not to smoke after last
Distributed to many > Warfarin: May interfere with dose of the day.
Routes: body tissues and warfarin clearance. Monitor > Caution patient to avoid activities that require
P.O appears in CSF patient closely for bleeding. alertness until response to the drug is known.
I.V Metabolism: liver Drug-lifestyle: > Inform patient that increased fluid and fiber
I.M Excretion: primarily in > Smoking: May increase intake and exercise may minimize constipation.
Source: the urine (30-70%) gastric acid secretion and > Advise patient to report onset of black, tarry
Schull, 2009, and feces worsen disease. Discourage stools, fever, sore throat, diarrhea, dizziness, rash,
Nursing using together Source: Schull, confusion, or hallucinations to the physician
Spectrum Half-life: 2 to 3 hours Source: Schull, Drug-Herb: 2009, Nursing immediately.
Source: Source: Drug 2009, Nursing Yerba mate: decreased drug Spectrum Drug
Schull, 2009, Handbook, Source: Schull, 2009, Spectrum Drug clearance Handbook, Source: Schull, 2009, Nursing Spectrum Drug
Nursing Spectrum McGrawhill Nursing Spectrum Handbook, Source: Schull, 2009, Nursing McGrawhill Handbook, McGrawhill
Drug Handbook, Drug Handbook, McGrawhill Spectrum Drug Handbook,
McGrawhill McGrawhill McGrawhill